Interpace Biosciences' Q4 revenue falls 26% after PancraGEN discontinuation
Overview
US thyroid diagnostics firm's Q4 revenue declined 26% yr/yr, reflecting PancraGEN discontinuation
Q4 net income from continuing operations benefited from a one-time, non-cash tax-related accounting adjustment
Q4 thyroid test volume and thyroid revenue both increased yr/yr
Outlook
Interpace expects approximately 16% yr-over-yr thyroid revenue growth in 2026
Company aims to scale thyroid test volume through deeper adoption and account growth
Interpace targets productivity gains via automation and operational discipline in 2026
Result Drivers
TAX-RELATED ADJUSTMENT - Q4 net income from cont. ops. was significantly boosted by a one-time, non-cash tax-related accounting adjustment related to the release of a deferred tax valuation allowance
THYROID TEST GROWTH - Q4 thyroid test volume increased 11% and thyroid revenue rose 14% yr/yr, reflecting growth in the core thyroid diagnostics business
Company press release: ID:nGNX4VLKMR
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue |
| $9.22 mln |
|
Q4 Net Income |
| $22.66 mln |
|
Q4 Gross Profit |
| $6.04 mln |
|
Q4 Operating Expenses |
| $4.47 mln |
|
Q4 Operating Income |
| $1.58 mln |
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
